Latest Breaking News On - Eventide asset management - Page 3 : comparemela.com

ACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 1-Year Low at $14 60

ACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 1-Year Low at $14 60
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

United statesRobertw bairdStephen davisStifel nicolausBrendan teehanEventide asset managementRoyal bankAcadia pharmaceuticals incPharmaceuticals incPharmaceuticals stockPharmaceuticals dailyPharmaceuticals company profileFred alger managementSecurities exchange commissionMg investment management ltdNorges bank

Celcuity Announces Pricing of Underwritten Common Stock Offering

Celcuity Announces Pricing of Underwritten Common Stock Offering
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesSan franciscoBrian sullivanMaria yonkoskiVicky hahneCelcuity incTd securities united statesNicolaus company incorporatedProspectus departmentGlobenewswire incLeerink partnersSyndicate departmentExchange commissionEventide asset managementCapital management

Decheng Capital LLC Acquires New Holdings in Aura Biosciences, Inc (NASDAQ:AURA)

Decheng Capital LLC Acquires New Holdings in Aura Biosciences, Inc (NASDAQ:AURA)
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Sg americas securitiesEventide asset managementDecheng capitalExchange traded conceptsAura biosciences incAura biosciencesFree reportAsset managementCapital partnersCapital managementTraded conceptsGet free reportVisit holdingschannelAura biosciences daily

Ardelyx (NASDAQ:ARDX) Rating Reiterated by Wedbush

Wedbush reissued their outperform rating on shares of Ardelyx (NASDAQ:ARDX – Free Report) in a report published on Friday, Benzinga reports. The firm currently has a $15.00 price target on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on ARDX. Citigroup increased their target price on shares of Ardelyx from […]

United statesLeerink partnrsPiper sandlerMichael raabPricet rowe associates incEventide asset managementArdelyx incVanguard group incArdelyx company profileSecurities exchange commissionFree reportModerate buyGet free reportRobert ora felschExchange commissionAsset management

Edmond DE Rothschild Holding S A Purchases 65,800 Shares of Denali Therapeutics Inc (NASDAQ:DNLI)

Edmond DE Rothschild Holding S.A. grew its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 65.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 165,680 shares of the company’s stock after buying an additional 65,800 shares during the […]

United statesStevee krognesVickil satoStifel nicolausGoldman sachs groupDenali therapeutics incNorges bankVanguard group incDenali therapeutics company profileEventide asset managementExchange commissionEdmond de rothschild holdingPrincipal financial group incDenali therapeuticsFree reportFinancial group